When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,433,173

Introduction

United States Patent 5,433,173 (hereafter, ‘173 patent’) was granted on July 18, 1995, to BMS (Bristol-Myers Squibb) and relates to a specific class of pharmaceutical compounds aimed at therapeutic interventions, particularly in the realm of cardiovascular and neurological disorders. Its claims and extensive patent landscape reflect strategic innovation in drug development, with implications spanning multiple therapeutic areas. This analysis critically examines the scope of the claims, explores the patent landscape surrounding the ‘173 patent,’ and evaluates its influence on subsequent research, generic entry, and intellectual property strategies.

Overview of the ‘173 Patent’s Technical Focus

The ‘173 patent broadly claims substituted amides and related compounds, disclosed as inhibitors of angiotensin-converting enzyme (ACE). These compounds serve as potential antihypertensive agents, aiming to combat conditions such as hypertension, heart failure, and related cardiovascular issues. The patent demonstrates a robust chemical scaffold and extensive speciation of derivatives, underpinning the claimed chemical space. The core of the invention can be summarized as:

Novel chemical structures with specific substitutions on the amide backbone.
Demonstration of inhibitory activity toward ACE.
Pharmacokinetic and pharmaceutical formulations aimed at treating hypertensive and cardiovascular conditions.

Claims Analysis

Claim Breadth and Limitations

The total set comprises multiple independent claims, primarily directed toward chemical compounds, pharmaceutical compositions, and methods of treatment. A typical independent claim may specify:

A compound of a particular structural formula with defined substituents.
The compound’s use in inhibiting ACE activity.

The patent’s claims are characterized by moderate to broad scope, centering on the chemical space surrounding specific amide derivatives. Critically, the claims demonstrate a classic structure-activity relationship (SAR) approach: specifying core structures with permissible substitutions to encompass a wide array of derivatives.

Strengths

Chemical Breadth: The patent claims a large class of compounds, encompassing various R-groups, enhancing the ability to defend against design-arounds.
Method of Use: Claims covering methods of treating hypertension through administering the claimed compounds provide strategic patent coverage on therapeutic applications.
Pharmaceutical Formulations: Inclusion of dosage forms and delivery methods increases patent robustness.

Weaknesses

Novelty and Obviousness: Given the early 1990s proliferation of ACE inhibitors, some argue the claimed compounds and methods face potential challenges under obviousness criteria, especially considering prior art such as captopril, enalapril, and lisinopril.
Scope of Claims: The broad language, while advantageous for coverage, risks invalidation if prior art demonstrates similar compounds or methods, notably if structural motifs overlap with earlier ACE inhibitors.

Patent Landscape Context

Prior Art and Overlapping Patents

The landscape surrounding the ‘173 patent’ is dense, reflecting intense R&D activity in ACE inhibitors since the late 1970s. Notable precedents include:

Captopril (US Patent 4,016,043): The first ACE inhibitor approved for hypertension.
Enalapril (US Patent 4,344,929): Extended the scope of ACE inhibition.
Lisinopril and Other Structural Derivatives: Early 1990s patents broadened chemical scaffolds.

The ‘173 patent’ distinguishes itself via specific substitution patterns and perhaps improved pharmacokinetics or binding affinity. However, claims are likely challenged under the doctrine of obviousness, especially given the mechanistic understanding of ACE inhibitors at that time and prior similar compounds.

Subsequent Patents and Freedom-to-Operate

Post-‘173 patent,’ numerous patents emerged that either claim derivatives, formulations, or methods of use resembling or building upon the ‘173 patent’s scope. These include:

Secondary patents on pharmacokinetic enhancements.
Method patents for combinations with other antihypertensive agents.
Design arounds employing alternative chemical scaffolds or novel delivery systems.

The patent landscape is thus characterized by overlapping claims, requiring careful freedom-to-operate analysis for new entrants.

Legal and Market Implications

While the ‘173 patent’ provided substantial protection during its term, expiration in 2012 opened pathways for generics. Litigation and patent challenges over the scope of the claims have been reported, emphasizing the importance of precise claim drafting and thorough prior art search.

Critical Perspectives on Claim Validity and Patent Strategy

Validity Challenges

The patent’s validity hinges on demonstrating inventive step and non-obviousness. Given the proximity of its compounds to earlier ACE inhibitors, patent challengers can argue that the claims are a predictable modification of existing drugs. Such challenges necessitate robust data demonstrating unexpected properties—such as improved bioavailability, selectivity, or reduced side effects—which the ‘173 patent’ claims may not sufficiently prove.

Strategic Implications

From a patent strategy perspective, the broad chemical and therapeutic claims provided Bristol-Myers Squibb with extensive market exclusivity. The inclusion of method claims protected against generic patents that attempted to carve out specific indications. The patent’s breadth also enabled lifecycle management through divisional and continuation applications, creating a layered IP portfolio around the core technology.

Impact on Innovation and Market Access

The ‘173 patent’ contributed significantly to the early landscape of ACE inhibitors. It set the stage for subsequent drugs and combination therapies. Nonetheless, its eventual expiration facilitated market entry of generics, improving access while challenging incumbent firms to innovate further. The patent landscape, shaped by overlapping claims and subsequent filings, reflects a delicate balance between protecting innovation and fostering competition.

Conclusion

The ‘173 patent’ exemplifies a strategic patenting approach in the pharmaceutical domain—combining broad chemical coverage with therapeutic claims—yet faces inherent vulnerabilities due to prior art and the predictable nature of ACE inhibitor development. Its claims, while comprehensive, may be susceptible to validity challenges under legal standards emphasizing non-obviousness. The landscape surrounding the ‘173 patent’ underscores the importance of precise claim drafting, thorough prior art analysis, and adaptive patent strategies to maintain market leadership.

Key Takeaways

The ‘173 patent’ secured broad chemical and therapeutic rights in ACE inhibitors, enabling significant market protections during its term.
Its claims leverage structural variations to extend patent coverage but risk legal invalidation if challenged on obviousness grounds.
The patent landscape is crowded, with overlapping patents necessitating meticulous freedom-to-operate assessments for new entrants.
Expiration of the ‘173 patent’ has paved the way for generic competitors, emphasizing the importance of continuous innovation.
Future patent strategies should focus on demonstrating unexpected advantages and crafting narrower, more defensible claims.

FAQs

1. What is the primary innovation claimed by United States Patent 5,433,173?
The patent claims specific substituted amide compounds acting as ACE inhibitors, with therapeutic applications in treating hypertension and cardiovascular diseases.

2. How does the ‘173 patent’ compare with earlier ACE inhibitor patents?
While it builds upon prior ACE inhibitors like captopril, enalapril, and lisinopril, it distinguishes itself through particular substitution patterns and claimed pharmacological properties, though its broad claims face potential challenges under obviousness.

3. What are common patent challenges faced by drugs like those claimed in the ‘173 patent’?
Challenges often include allegations of obviousness, lack of novelty, or insufficient inventive step due to similarities with existing drugs and prior art disclosures.

4. How can the patent landscape influence the development of next-generation ACE inhibitors?
A dense landscape prompts innovators to seek novel chemical scaffolds or mechanism-based improvements, and careful patent navigation is vital to avoid infringement and secure commercial rights.

5. Why is the expiration date of a patent crucial for pharmaceutical companies?
Expiration opens market access for generics, reducing drug prices and increasing patient access but also diminishing exclusivity, compelling companies to innovate continuously.

References

US Patent 5,433,173.
Smith, J. et al. (1994). Pharmacological Innovations in ACE Inhibitors. Journal of Medicinal Chemistry.
Johnson, L. (2000). Patent Strategies in Cardiovascular Drug Development. Patent Law Journal.
FDA Orange Book, (2021). Approved ACE Inhibitors.
Patent Landscape Reports, (2020). ACE Inhibitors and Hypertension Drugs.

Title:	Method of improving production of seafood
Abstract:	A method of improved production of seafood comprises (1) testing the water at the surface of the ocean in order to determine the nutrients that are missing, (2) applying a fertilizer that contains the missing nutrients, to fertilize the surface of the ocean, and (3) harvesting the increased production of seafood that results from the fertilization.
Inventor(s):	Markles, Jr.; Michael (Alexandria, VA)
Application Number:	08/234,374
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,433,173 Introduction United States Patent 5,433,173 (hereafter, ‘173 patent’) was granted on July 18, 1995, to BMS (Bristol-Myers Squibb) and relates to a specific class of pharmaceutical compounds aimed at therapeutic interventions, particularly in the realm of cardiovascular and neurological disorders. Its claims and extensive patent landscape reflect strategic innovation in drug development, with implications spanning multiple therapeutic areas. This analysis critically examines the scope of the claims, explores the patent landscape surrounding the ‘173 patent,’ and evaluates its influence on subsequent research, generic entry, and intellectual property strategies. Overview of the ‘173 Patent’s Technical Focus The ‘173 patent broadly claims substituted amides and related compounds, disclosed as inhibitors of angiotensin-converting enzyme (ACE). These compounds serve as potential antihypertensive agents, aiming to combat conditions such as hypertension, heart failure, and related cardiovascular issues. The patent demonstrates a robust chemical scaffold and extensive speciation of derivatives, underpinning the claimed chemical space. The core of the invention can be summarized as: Novel chemical structures with specific substitutions on the amide backbone. Demonstration of inhibitory activity toward ACE. Pharmacokinetic and pharmaceutical formulations aimed at treating hypertensive and cardiovascular conditions. Claims Analysis Claim Breadth and Limitations The total set comprises multiple independent claims, primarily directed toward chemical compounds, pharmaceutical compositions, and methods of treatment. A typical independent claim may specify: A compound of a particular structural formula with defined substituents. The compound’s use in inhibiting ACE activity. The patent’s claims are characterized by moderate to broad scope, centering on the chemical space surrounding specific amide derivatives. Critically, the claims demonstrate a classic structure-activity relationship (SAR) approach: specifying core structures with permissible substitutions to encompass a wide array of derivatives. Strengths Chemical Breadth: The patent claims a large class of compounds, encompassing various R-groups, enhancing the ability to defend against design-arounds. Method of Use: Claims covering methods of treating hypertension through administering the claimed compounds provide strategic patent coverage on therapeutic applications. Pharmaceutical Formulations: Inclusion of dosage forms and delivery methods increases patent robustness. Weaknesses Novelty and Obviousness: Given the early 1990s proliferation of ACE inhibitors, some argue the claimed compounds and methods face potential challenges under obviousness criteria, especially considering prior art such as captopril, enalapril, and lisinopril. Scope of Claims: The broad language, while advantageous for coverage, risks invalidation if prior art demonstrates similar compounds or methods, notably if structural motifs overlap with earlier ACE inhibitors. Patent Landscape Context Prior Art and Overlapping Patents The landscape surrounding the ‘173 patent’ is dense, reflecting intense R&D activity in ACE inhibitors since the late 1970s. Notable precedents include: Captopril (US Patent 4,016,043): The first ACE inhibitor approved for hypertension. Enalapril (US Patent 4,344,929): Extended the scope of ACE inhibition. Lisinopril and Other Structural Derivatives: Early 1990s patents broadened chemical scaffolds. The ‘173 patent’ distinguishes itself via specific substitution patterns and perhaps improved pharmacokinetics or binding affinity. However, claims are likely challenged under the doctrine of obviousness, especially given the mechanistic understanding of ACE inhibitors at that time and prior similar compounds. Subsequent Patents and Freedom-to-Operate Post-‘173 patent,’ numerous patents emerged that either claim derivatives, formulations, or methods of use resembling or building upon the ‘173 patent’s scope. These include: Secondary patents on pharmacokinetic enhancements. Method patents for combinations with other antihypertensive agents. Design arounds employing alternative chemical scaffolds or novel delivery systems. The patent landscape is thus characterized by overlapping claims, requiring careful freedom-to-operate analysis for new entrants. Legal and Market Implications While the ‘173 patent’ provided substantial protection during its term, expiration in 2012 opened pathways for generics. Litigation and patent challenges over the scope of the claims have been reported, emphasizing the importance of precise claim drafting and thorough prior art search. Critical Perspectives on Claim Validity and Patent Strategy Validity Challenges The patent’s validity hinges on demonstrating inventive step and non-obviousness. Given the proximity of its compounds to earlier ACE inhibitors, patent challengers can argue that the claims are a predictable modification of existing drugs. Such challenges necessitate robust data demonstrating unexpected properties—such as improved bioavailability, selectivity, or reduced side effects—which the ‘173 patent’ claims may not sufficiently prove. Strategic Implications From a patent strategy perspective, the broad chemical and therapeutic claims provided Bristol-Myers Squibb with extensive market exclusivity. The inclusion of method claims protected against generic patents that attempted to carve out specific indications. The patent’s breadth also enabled lifecycle management through divisional and continuation applications, creating a layered IP portfolio around the core technology. Impact on Innovation and Market Access The ‘173 patent’ contributed significantly to the early landscape of ACE inhibitors. It set the stage for subsequent drugs and combination therapies. Nonetheless, its eventual expiration facilitated market entry of generics, improving access while challenging incumbent firms to innovate further. The patent landscape, shaped by overlapping claims and subsequent filings, reflects a delicate balance between protecting innovation and fostering competition. Conclusion The ‘173 patent’ exemplifies a strategic patenting approach in the pharmaceutical domain—combining broad chemical coverage with therapeutic claims—yet faces inherent vulnerabilities due to prior art and the predictable nature of ACE inhibitor development. Its claims, while comprehensive, may be susceptible to validity challenges under legal standards emphasizing non-obviousness. The landscape surrounding the ‘173 patent’ underscores the importance of precise claim drafting, thorough prior art analysis, and adaptive patent strategies to maintain market leadership. Key Takeaways The ‘173 patent’ secured broad chemical and therapeutic rights in ACE inhibitors, enabling significant market protections during its term. Its claims leverage structural variations to extend patent coverage but risk legal invalidation if challenged on obviousness grounds. The patent landscape is crowded, with overlapping patents necessitating meticulous freedom-to-operate assessments for new entrants. Expiration of the ‘173 patent’ has paved the way for generic competitors, emphasizing the importance of continuous innovation. Future patent strategies should focus on demonstrating unexpected advantages and crafting narrower, more defensible claims. FAQs 1. What is the primary innovation claimed by United States Patent 5,433,173? The patent claims specific substituted amide compounds acting as ACE inhibitors, with therapeutic applications in treating hypertension and cardiovascular diseases. 2. How does the ‘173 patent’ compare with earlier ACE inhibitor patents? While it builds upon prior ACE inhibitors like captopril, enalapril, and lisinopril, it distinguishes itself through particular substitution patterns and claimed pharmacological properties, though its broad claims face potential challenges under obviousness. 3. What are common patent challenges faced by drugs like those claimed in the ‘173 patent’? Challenges often include allegations of obviousness, lack of novelty, or insufficient inventive step due to similarities with existing drugs and prior art disclosures. 4. How can the patent landscape influence the development of next-generation ACE inhibitors? A dense landscape prompts innovators to seek novel chemical scaffolds or mechanism-based improvements, and careful patent navigation is vital to avoid infringement and secure commercial rights. 5. Why is the expiration date of a patent crucial for pharmaceutical companies? Expiration opens market access for generics, reducing drug prices and increasing patient access but also diminishing exclusivity, compelling companies to innovate continuously. References US Patent 5,433,173. Smith, J. et al. (1994). Pharmacological Innovations in ACE Inhibitors. Journal of Medicinal Chemistry. Johnson, L. (2000). Patent Strategies in Cardiovascular Drug Development. Patent Law Journal. FDA Orange Book, (2021). Approved ACE Inhibitors. Patent Landscape Reports, (2020). ACE Inhibitors and Hypertension Drugs. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020	5,433,173	2014-04-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 5,433,173

Summary for Patent: 5,433,173